IDYN - ETF AI Analysis
Top Page
iShares International Equity Factor Rotation Active ETF (IDYN)
Rating:59Neutral
Price Target:―
Positive Factors
Solid Year-to-Date Performance
The ETF has delivered strong gains so far this year, showing that its strategy has worked well in the recent market environment.
Supportive Top Holdings
Several of the largest positions, including major financial and industrial companies, have shown strong performance, helping lift the fund overall.
Broad International Diversification
The fund spreads its investments across many countries such as Japan, the U.S., the UK, and key European markets, which helps reduce reliance on any single economy.
Negative Factors
Moderate Expense Ratio
The fund’s fees are higher than many simple index ETFs, which slightly reduces the net return investors take home.
Mixed Performance Among Top Holdings
Some major positions, such as AstraZeneca and Enel, have shown weak or flat performance, which can drag on the fund’s overall results.
Short-Term Performance Softness
Recent one-month and three-month returns have been flat to slightly negative, suggesting the fund’s momentum has cooled in the near term.
IDYN vs. SPDR S&P 500 ETF (SPY)
AUM113.31M
RegionGlobal Ex-U.S.
Expense Ratio0.45%
Beta0.85
IssueriShares
Inception DateAug 05, 2025
Dividend Yield1.84%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume35,999
30 Day Avg. Volume18,070
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
34.53Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering200
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IDYN Summary
IDYN is an actively managed ETF that invests in a wide mix of large and mid-sized companies outside the U.S., aiming to follow a broad international market theme rather than a specific index. It holds well-known global names like Novartis and AstraZeneca, along with banks, industrial firms, and utilities across countries such as Japan, the UK, and Germany, plus some emerging markets. Investors might consider IDYN for international diversification and the potential for growth in both developed and developing economies. However, its value can go up and down with global stock markets, and performance depends on the manager’s factor rotation strategy.
How much will it cost me?This ETF has an expense ratio of 0.45%, which means you’ll pay about $4.50 per year for every $1,000 you invest. That’s higher than the cost of many simple index ETFs because this fund is actively managed and uses a factor-rotation strategy that requires more research and trading.
What would affect this ETF?This ETF could benefit if international economic growth improves, especially in Europe and other markets outside the U.S., boosting industrial, financial, and healthcare companies like ASML, Novartis, and AstraZeneca, and if global stock markets reward the fund’s flexible, factor-based strategy. On the other hand, it could be hurt by slower growth or financial stress in non-U.S. economies, rising interest rates that pressure banks and utilities, energy or regulatory shocks affecting companies like Enel and Siemens Energy, or if its active rotation strategy picks factors that fall out of favor.
IDYN Top 10 Holdings
IDYN leans heavily on big European financials and utilities, with Mitsubishi UFJ and Banco Santander acting as key engines of recent gains as their shares keep rising. Telecom giant Vodafone has also been a bright spot, adding some extra lift with strong momentum. On the other side, defensive names like Novartis and Enel have been more mixed, occasionally losing steam and tempering overall performance. With broad exposure across developed markets and room for emerging markets, the fund’s story is global ex-U.S., but its near-term results are being written mostly by banks, utilities, and telecoms.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Novartis AG | 2.83% | $3.22M | CHF218.02B | 13.47% | 80 Outperform | |
| AstraZeneca | 2.23% | $2.53M | $246.54B | -6.13% | 80 Outperform | |
| Iberdrola | 2.02% | $2.29M | €140.20B | 28.61% | 67 Neutral | |
| Banco Santander SA | 1.77% | $2.01M | $195.98B | 38.36% | 72 Outperform | |
| Enel S.p.A. | 1.65% | $1.87M | €88.03B | 6.50% | 67 Neutral | |
| ― | 1.57% | $1.79M | ― | ― | ― | |
| Mitsubishi UFJ Financial Group | 1.57% | $1.78M | ¥38.71T | 52.68% | 76 Outperform | |
| Assicurazioni Generali S.p.A. | 1.46% | $1.66M | €62.60B | 25.79% | 63 Neutral | |
| ABB Ltd | 1.44% | $1.63M | kr1.72T | 36.32% | 78 Outperform | |
| Vodafone | 1.42% | $1.62M | £27.42B | 38.52% | 63 Neutral |
IDYN Technical Analysis
Negative
―
Price Trends
30.74
Negative
30.37
Negative
29.92
Positive
Market Momentum
-0.21
Positive
40.45
Neutral
15.86
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IDYN, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 30.46, equal to the 50-day MA of 30.74, and equal to the 200-day MA of 29.92, indicating a neutral trend. The MACD of -0.21 indicates Positive momentum. The RSI at 40.45 is Neutral, neither overbought nor oversold. The STOCH value of 15.86 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IDYN.
IDYN Peer Comparison
Comparison Results
Performance Comparison
IDYN
iShares International Equity Factor Rotation Active ETF
29.95
3.77
14.40%
JDVI
John Hancock Disciplined Value International Select ETF
―
―
―
OSEA
Harbor International Compounders ETF
―
―
―
AVDS
Avantis International Small Cap Equity ETF
―
―
―
QLTI
GMO International Quality ETF
―
―
―
BAIV
Brown Advisory International Value Select ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents